Geographic atrophy

Jun 07, 2024

Wet AMD, comprising around 10% of the total AMD population, is primarily the target of pharmaceutical companies, representing a market worth billions of dollars. With only two FDA-approved treatments, dry AMD presents a substantial market potential, encompassing approximately 90% of all AMD patients. Key players...

Apr 02, 2024

Voydeya Receives FDA Approval as Supplemental Treatment with Ravulizumab or Eculizumab for Managing Extravascular Hemolysis in Adult Patients with PNH Voydeya (danicopan) has received approval in the United States for use alongside ravulizumab or eculizumab in treating extravascular hemolysis (EVH) in adults dia...

Aug 18, 2023

Globally, more than 5 million people are affected by geographic atrophy. Also, as per the published study by the GER group, the global prevalence of geographic atrophy is 0.66% in all ages, but it occurs in 0.34% for 65–74 years old, 1.3% for 75–84, and 4.4% over 85 years old. Geographic atrophy is a progressive, i...

Apr 18, 2023

RegeneRx Biopharmaceuticals Enrolled First Patient in the Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259 in the US On April 12, 2023, RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company") announced that the first patient of Phase 3 clinical trial (SEER-2) of RGN-259, a novel treat...

Feb 21, 2023

Actinium Announces Positive Full Data Results From the Pivotal Phase III SIERRA Trial Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, announced positive primary and secondary endpoint results from its pivotal Phase III SIERRA trial of Iomab-B in patients aged 55 and older...

Dec 21, 2021

Edwards secures FDA approval for Sapien 3 with Alterra Prestent for Transcatheter Pulmonic Valve Replacement Edwards Lifesciences declared to receive approval from the U.S. Food and Drug Administration (FDA) to use the Edwards SAPIEN 3 transcatheter valve with the Alterra adaptive prestent (SAPIEN 3 with Alterra...

Jun 22, 2020

The Geographic atrophy market size is anticipated to increase during the study period 2017–2030 owing to increasing GA prevalence, better understanding of disease pathophysiology, better therapies and pipeline candidates aimed at addressing the disease from its root. Geographic Atrophy (GA) is an advanced form ...

Oct 30, 2019

Geographic atrophy (GA) is a severe, progressive, irreversible vision loss in old age people. The loss in the vision is due to the damage in a small portion of the retina at the back of the eye, known as the macula. Since the loss of vision is due to age, it is also referred to as Age-related macular degeneration. ...